We use cookies to provide you with the best of services and customized features. By continuing to browse this website, you give your informed consent to our Cookie Policy.
Prestige Biopharma said on Friday that it signed a memorandum of understanding (MOU) with Imagion Biosystems, a U.S. imaging diagnostics company, to develop an early diagnosis platform for pancreatic cancer.